| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Multiple Myeloma | 270 | 2024 | 5196 | 8.720 |
Why?
|
| Boronic Acids | 80 | 2024 | 915 | 4.430 |
Why?
|
| Pyrazines | 81 | 2024 | 1205 | 3.950 |
Why?
|
| Protease Inhibitors | 36 | 2014 | 751 | 2.530 |
Why?
|
| Antineoplastic Agents | 110 | 2024 | 13676 | 1.950 |
Why?
|
| Thalidomide | 40 | 2017 | 886 | 1.600 |
Why?
|
| Apoptosis | 108 | 2024 | 9523 | 1.510 |
Why?
|
| Interleukin-6 | 56 | 2024 | 3228 | 1.500 |
Why?
|
| Histone Deacetylase Inhibitors | 14 | 2018 | 778 | 1.480 |
Why?
|
| Bone Marrow | 33 | 2021 | 2935 | 1.140 |
Why?
|
| Proteasome Endopeptidase Complex | 36 | 2017 | 1319 | 1.130 |
Why?
|
| NF-kappa B | 34 | 2021 | 2493 | 1.120 |
Why?
|
| Tumor Cells, Cultured | 81 | 2021 | 6124 | 1.100 |
Why?
|
| Proto-Oncogene Proteins c-akt | 23 | 2024 | 2457 | 1.080 |
Why?
|
| I-kappa B Kinase | 6 | 2014 | 250 | 1.080 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 6 | 2024 | 693 | 1.060 |
Why?
|
| Signal Transduction | 62 | 2024 | 23645 | 1.000 |
Why?
|
| Bone Marrow Cells | 42 | 2011 | 2414 | 0.940 |
Why?
|
| Phosphorylcholine | 12 | 2012 | 153 | 0.910 |
Why?
|
| Cell Line, Tumor | 87 | 2024 | 17140 | 0.880 |
Why?
|
| Immunologic Factors | 13 | 2020 | 1596 | 0.880 |
Why?
|
| Enzyme Inhibitors | 34 | 2018 | 3728 | 0.810 |
Why?
|
| Neoplasm Proteins | 19 | 2017 | 3603 | 0.810 |
Why?
|
| Phosphatidylinositol 3-Kinases | 9 | 2024 | 2885 | 0.730 |
Why?
|
| Hydroxamic Acids | 8 | 2016 | 483 | 0.710 |
Why?
|
| Dexamethasone | 40 | 2014 | 1965 | 0.690 |
Why?
|
| ZAP-70 Protein-Tyrosine Kinase | 1 | 2020 | 69 | 0.690 |
Why?
|
| Cell Proliferation | 48 | 2024 | 10474 | 0.650 |
Why?
|
| Stromal Cells | 34 | 2011 | 1336 | 0.640 |
Why?
|
| Drug Resistance, Neoplasm | 39 | 2024 | 5341 | 0.630 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 11 | 2012 | 440 | 0.620 |
Why?
|
| Phosphorylation | 38 | 2020 | 8317 | 0.610 |
Why?
|
| Mice, SCID | 36 | 2017 | 2627 | 0.610 |
Why?
|
| Cell Adhesion | 31 | 2016 | 3096 | 0.600 |
Why?
|
| Histone Deacetylases | 6 | 2019 | 717 | 0.580 |
Why?
|
| Terphenyl Compounds | 1 | 2016 | 7 | 0.560 |
Why?
|
| Gene Expression Regulation, Neoplastic | 32 | 2023 | 8647 | 0.560 |
Why?
|
| Down-Regulation | 20 | 2016 | 2937 | 0.560 |
Why?
|
| Cell Survival | 38 | 2017 | 5777 | 0.540 |
Why?
|
| Adaptor Proteins, Signal Transducing | 5 | 2024 | 2909 | 0.520 |
Why?
|
| Caspases | 24 | 2013 | 882 | 0.520 |
Why?
|
| Mitogen-Activated Protein Kinases | 11 | 2007 | 1245 | 0.510 |
Why?
|
| Cell Division | 32 | 2013 | 4473 | 0.470 |
Why?
|
| Xenograft Model Antitumor Assays | 33 | 2024 | 3611 | 0.470 |
Why?
|
| Drug Synergism | 31 | 2014 | 1760 | 0.470 |
Why?
|
| Killer Cells, Natural | 6 | 2024 | 2211 | 0.460 |
Why?
|
| Multienzyme Complexes | 12 | 2004 | 664 | 0.460 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 36 | 2018 | 11878 | 0.450 |
Why?
|
| Transcription Factor RelA | 2 | 2014 | 252 | 0.420 |
Why?
|
| I-kappa B Proteins | 7 | 2014 | 210 | 0.420 |
Why?
|
| Osteoclasts | 11 | 2013 | 713 | 0.410 |
Why?
|
| Acyltransferases | 2 | 2005 | 306 | 0.410 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 9 | 2017 | 2892 | 0.410 |
Why?
|
| HSP90 Heat-Shock Proteins | 9 | 2015 | 423 | 0.390 |
Why?
|
| Humans | 297 | 2024 | 768166 | 0.390 |
Why?
|
| Insulin-Like Growth Factor I | 22 | 2010 | 1942 | 0.390 |
Why?
|
| Cell Communication | 10 | 2009 | 1660 | 0.370 |
Why?
|
| Ubiquitin-Protein Ligases | 2 | 2020 | 1901 | 0.370 |
Why?
|
| Hematologic Neoplasms | 8 | 2023 | 1907 | 0.360 |
Why?
|
| Enzyme Activation | 21 | 2010 | 3590 | 0.360 |
Why?
|
| Microtubule-Associated Proteins | 2 | 2024 | 1074 | 0.360 |
Why?
|
| Proto-Oncogene Proteins | 14 | 2015 | 4528 | 0.340 |
Why?
|
| Cysteine Proteinase Inhibitors | 4 | 2007 | 185 | 0.340 |
Why?
|
| Waldenstrom Macroglobulinemia | 7 | 2022 | 1077 | 0.340 |
Why?
|
| Nicotinamide Phosphoribosyltransferase | 3 | 2016 | 85 | 0.330 |
Why?
|
| Janus Kinases | 4 | 2020 | 253 | 0.330 |
Why?
|
| Cell Cycle | 21 | 2017 | 2932 | 0.330 |
Why?
|
| Apoptosis Regulatory Proteins | 10 | 2024 | 1151 | 0.320 |
Why?
|
| Cytokines | 17 | 2016 | 7453 | 0.320 |
Why?
|
| Animals | 99 | 2024 | 169246 | 0.320 |
Why?
|
| Tumor Microenvironment | 11 | 2023 | 3948 | 0.310 |
Why?
|
| Mice | 75 | 2024 | 82029 | 0.310 |
Why?
|
| MAP Kinase Signaling System | 10 | 2015 | 1494 | 0.310 |
Why?
|
| Poly(ADP-ribose) Polymerases | 13 | 2016 | 428 | 0.310 |
Why?
|
| Tumor Necrosis Factor-alpha | 15 | 2006 | 4352 | 0.310 |
Why?
|
| DNA-Binding Proteins | 17 | 2013 | 9615 | 0.290 |
Why?
|
| Blotting, Western | 15 | 2017 | 5027 | 0.290 |
Why?
|
| Molecular Targeted Therapy | 7 | 2017 | 2830 | 0.290 |
Why?
|
| Vascular Endothelial Growth Factor A | 22 | 2009 | 3514 | 0.280 |
Why?
|
| Dose-Response Relationship, Drug | 28 | 2017 | 10760 | 0.280 |
Why?
|
| Imidazoles | 9 | 2015 | 1169 | 0.280 |
Why?
|
| DNA Damage | 7 | 2015 | 2469 | 0.280 |
Why?
|
| Heat-Shock Proteins | 10 | 2008 | 797 | 0.280 |
Why?
|
| Drug Evaluation, Preclinical | 10 | 2012 | 1338 | 0.270 |
Why?
|
| Cell Movement | 19 | 2016 | 5210 | 0.260 |
Why?
|
| Neovascularization, Pathologic | 17 | 2012 | 2631 | 0.260 |
Why?
|
| Antibodies, Monoclonal | 17 | 2020 | 9263 | 0.260 |
Why?
|
| Mucin-1 | 4 | 2017 | 537 | 0.260 |
Why?
|
| Cysteine Endopeptidases | 12 | 2004 | 542 | 0.260 |
Why?
|
| Oncogene Protein v-akt | 1 | 2006 | 130 | 0.260 |
Why?
|
| Proteins | 6 | 2012 | 6009 | 0.260 |
Why?
|
| STAT3 Transcription Factor | 10 | 2011 | 874 | 0.250 |
Why?
|
| Angiogenesis Inhibitors | 11 | 2009 | 2056 | 0.250 |
Why?
|
| Telomerase | 8 | 2016 | 751 | 0.250 |
Why?
|
| T-Lymphocytes, Cytotoxic | 5 | 2021 | 1801 | 0.250 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 9 | 2013 | 1656 | 0.250 |
Why?
|
| Melphalan | 9 | 2015 | 421 | 0.250 |
Why?
|
| Drug Screening Assays, Antitumor | 9 | 2015 | 719 | 0.240 |
Why?
|
| Chemokines, CXC | 2 | 2007 | 420 | 0.240 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 11 | 2012 | 1406 | 0.240 |
Why?
|
| Flow Cytometry | 15 | 2013 | 5902 | 0.240 |
Why?
|
| Drug Resistance, Multiple | 3 | 2005 | 255 | 0.230 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 7 | 2012 | 474 | 0.230 |
Why?
|
| Arsenicals | 5 | 2017 | 117 | 0.230 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 7 | 2012 | 478 | 0.230 |
Why?
|
| Endothelial Growth Factors | 7 | 2003 | 671 | 0.230 |
Why?
|
| Caspase 9 | 8 | 2008 | 184 | 0.220 |
Why?
|
| Doxorubicin | 13 | 2015 | 2234 | 0.220 |
Why?
|
| Cytotoxicity, Immunologic | 7 | 2020 | 1353 | 0.220 |
Why?
|
| Etodolac | 4 | 2007 | 19 | 0.220 |
Why?
|
| Lymphokines | 7 | 2003 | 924 | 0.220 |
Why?
|
| Neural Cell Adhesion Molecules | 1 | 2003 | 122 | 0.220 |
Why?
|
| Immunoblotting | 9 | 2009 | 1647 | 0.220 |
Why?
|
| RNA, Small Interfering | 12 | 2017 | 3428 | 0.210 |
Why?
|
| Adjuvants, Immunologic | 6 | 2006 | 998 | 0.210 |
Why?
|
| Pyrimidines | 10 | 2020 | 3048 | 0.210 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 6 | 2021 | 637 | 0.210 |
Why?
|
| Membrane Glycoproteins | 10 | 2020 | 3711 | 0.210 |
Why?
|
| Caspase 3 | 7 | 2016 | 730 | 0.210 |
Why?
|
| Ubiquitin | 8 | 2012 | 843 | 0.210 |
Why?
|
| Oxides | 5 | 2017 | 403 | 0.210 |
Why?
|
| Protein Kinase Inhibitors | 7 | 2022 | 5703 | 0.210 |
Why?
|
| Proto-Oncogene Proteins c-myc | 5 | 2021 | 998 | 0.210 |
Why?
|
| Coculture Techniques | 14 | 2016 | 1340 | 0.200 |
Why?
|
| beta Catenin | 5 | 2016 | 1047 | 0.200 |
Why?
|
| Tubulin | 3 | 2016 | 695 | 0.200 |
Why?
|
| Heterocyclic Compounds, 3-Ring | 4 | 2014 | 296 | 0.200 |
Why?
|
| Histone Deacetylase 1 | 1 | 2023 | 133 | 0.200 |
Why?
|
| Receptors, CXCR4 | 3 | 2016 | 729 | 0.200 |
Why?
|
| Clinical Trials as Topic | 19 | 2018 | 8054 | 0.200 |
Why?
|
| Amino Acyl-tRNA Synthetases | 1 | 2023 | 88 | 0.200 |
Why?
|
| Vascular Endothelial Growth Factors | 8 | 2006 | 748 | 0.190 |
Why?
|
| Up-Regulation | 15 | 2010 | 4146 | 0.190 |
Why?
|
| Lactones | 4 | 2008 | 316 | 0.190 |
Why?
|
| Benzimidazoles | 4 | 2015 | 864 | 0.180 |
Why?
|
| Mesenchymal Stem Cells | 3 | 2019 | 1672 | 0.170 |
Why?
|
| Transplantation, Heterologous | 15 | 2012 | 2393 | 0.170 |
Why?
|
| Lysosomes | 1 | 2005 | 938 | 0.170 |
Why?
|
| Lymphocyte Activation | 8 | 2021 | 5505 | 0.170 |
Why?
|
| Lymphoma, B-Cell | 2 | 2022 | 945 | 0.170 |
Why?
|
| STAT Transcription Factors | 1 | 2020 | 189 | 0.170 |
Why?
|
| Antibody-Dependent Cell Cytotoxicity | 5 | 2007 | 306 | 0.170 |
Why?
|
| Tumor Suppressor Proteins | 5 | 2017 | 2810 | 0.170 |
Why?
|
| Acetylation | 5 | 2018 | 1056 | 0.170 |
Why?
|
| Cells, Cultured | 15 | 2020 | 19015 | 0.170 |
Why?
|
| Quinazolinones | 2 | 2012 | 219 | 0.160 |
Why?
|
| Protein Kinase C | 4 | 2008 | 1207 | 0.160 |
Why?
|
| Monoclonal Gammopathy of Undetermined Significance | 1 | 2021 | 179 | 0.160 |
Why?
|
| Growth Substances | 3 | 2006 | 759 | 0.160 |
Why?
|
| Gene Knockdown Techniques | 4 | 2017 | 1606 | 0.160 |
Why?
|
| Anilides | 2 | 2016 | 413 | 0.160 |
Why?
|
| NAD | 2 | 2013 | 618 | 0.160 |
Why?
|
| Lysine | 2 | 2021 | 1000 | 0.160 |
Why?
|
| Protein-Tyrosine Kinases | 6 | 2016 | 2433 | 0.150 |
Why?
|
| Herpesvirus 8, Human | 4 | 2002 | 256 | 0.150 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 11 | 2016 | 3800 | 0.150 |
Why?
|
| Galectins | 1 | 2021 | 295 | 0.150 |
Why?
|
| Osteoblasts | 5 | 2013 | 1145 | 0.150 |
Why?
|
| Pyrroles | 5 | 2008 | 1124 | 0.150 |
Why?
|
| Neoplasm Transplantation | 8 | 2014 | 2014 | 0.150 |
Why?
|
| Leukocytes, Mononuclear | 4 | 2021 | 1854 | 0.150 |
Why?
|
| MicroRNAs | 3 | 2023 | 3803 | 0.150 |
Why?
|
| Sirolimus | 4 | 2014 | 1540 | 0.150 |
Why?
|
| Antigens, CD | 5 | 2021 | 4035 | 0.140 |
Why?
|
| Genes, ras | 2 | 2015 | 663 | 0.140 |
Why?
|
| Piperidines | 4 | 2016 | 1667 | 0.140 |
Why?
|
| Acrylamides | 3 | 2016 | 261 | 0.140 |
Why?
|
| Active Transport, Cell Nucleus | 3 | 2014 | 432 | 0.140 |
Why?
|
| Gene Expression Profiling | 16 | 2015 | 9538 | 0.140 |
Why?
|
| Caspase 8 | 4 | 2008 | 198 | 0.140 |
Why?
|
| Ikaros Transcription Factor | 1 | 2018 | 233 | 0.140 |
Why?
|
| Myeloid Differentiation Factor 88 | 2 | 2023 | 582 | 0.140 |
Why?
|
| Sulfides | 1 | 2017 | 171 | 0.140 |
Why?
|
| MAP Kinase Kinase 4 | 4 | 2008 | 147 | 0.140 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 3 | 2012 | 362 | 0.140 |
Why?
|
| Estradiol | 5 | 2004 | 1951 | 0.130 |
Why?
|
| Cell Death | 7 | 2017 | 1679 | 0.130 |
Why?
|
| Protein Processing, Post-Translational | 2 | 2018 | 1966 | 0.130 |
Why?
|
| Maytansine | 2 | 2009 | 88 | 0.130 |
Why?
|
| Syndecan-1 | 5 | 2009 | 163 | 0.130 |
Why?
|
| Histones | 4 | 2024 | 2601 | 0.130 |
Why?
|
| G1 Phase | 2 | 2012 | 403 | 0.130 |
Why?
|
| Spiro Compounds | 2 | 2007 | 69 | 0.130 |
Why?
|
| B-Lymphocytes | 8 | 2023 | 4793 | 0.130 |
Why?
|
| Morpholines | 2 | 2014 | 584 | 0.130 |
Why?
|
| Immunomodulation | 1 | 2020 | 549 | 0.130 |
Why?
|
| MAP Kinase Kinase 1 | 4 | 2010 | 331 | 0.130 |
Why?
|
| Blood Proteins | 1 | 2021 | 1191 | 0.130 |
Why?
|
| Stem Cell Transplantation | 5 | 2010 | 1596 | 0.130 |
Why?
|
| Peptide Hydrolases | 1 | 2018 | 610 | 0.120 |
Why?
|
| Myeloid Cells | 2 | 2013 | 839 | 0.120 |
Why?
|
| Tumor Suppressor Protein p53 | 5 | 2012 | 2954 | 0.120 |
Why?
|
| Cyclophilin A | 1 | 2015 | 57 | 0.120 |
Why?
|
| Nuclear Proteins | 5 | 2023 | 5804 | 0.120 |
Why?
|
| Jumonji Domain-Containing Histone Demethylases | 1 | 2016 | 168 | 0.120 |
Why?
|
| Plasmacytoma | 3 | 2012 | 170 | 0.120 |
Why?
|
| Mitochondrial Proteins | 4 | 2006 | 979 | 0.120 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 3 | 2021 | 615 | 0.120 |
Why?
|
| T-Lymphocyte Subsets | 2 | 2020 | 1815 | 0.120 |
Why?
|
| Response Elements | 1 | 2016 | 307 | 0.120 |
Why?
|
| Cell Line | 11 | 2013 | 15597 | 0.120 |
Why?
|
| Models, Biological | 11 | 2016 | 9495 | 0.120 |
Why?
|
| Purines | 2 | 2010 | 615 | 0.120 |
Why?
|
| Interferon Regulatory Factors | 1 | 2016 | 271 | 0.110 |
Why?
|
| Benzoquinones | 4 | 2008 | 198 | 0.110 |
Why?
|
| Epitopes, T-Lymphocyte | 1 | 2018 | 827 | 0.110 |
Why?
|
| Proteoglycans | 4 | 2005 | 809 | 0.110 |
Why?
|
| Diphosphonates | 2 | 2009 | 634 | 0.110 |
Why?
|
| Indoles | 5 | 2013 | 1836 | 0.110 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 7 | 2013 | 4580 | 0.110 |
Why?
|
| Drug Delivery Systems | 8 | 2017 | 2232 | 0.110 |
Why?
|
| Antineoplastic Agents, Phytogenic | 3 | 2009 | 622 | 0.110 |
Why?
|
| Plasma Cells | 2 | 2022 | 599 | 0.110 |
Why?
|
| Prognosis | 10 | 2021 | 30010 | 0.110 |
Why?
|
| Intercellular Adhesion Molecule-1 | 5 | 2009 | 1134 | 0.110 |
Why?
|
| Viral Proteins | 2 | 2000 | 1802 | 0.110 |
Why?
|
| Recurrence | 14 | 2014 | 8509 | 0.110 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 3 | 2006 | 662 | 0.110 |
Why?
|
| Lactams, Macrocyclic | 4 | 2008 | 319 | 0.100 |
Why?
|
| Pyridines | 5 | 2023 | 2894 | 0.100 |
Why?
|
| Kruppel-Like Transcription Factors | 1 | 2016 | 507 | 0.100 |
Why?
|
| Cell Growth Processes | 6 | 2014 | 381 | 0.100 |
Why?
|
| Sirtuins | 1 | 2015 | 322 | 0.100 |
Why?
|
| TOR Serine-Threonine Kinases | 5 | 2014 | 2062 | 0.100 |
Why?
|
| Cryoglobulins | 1 | 2012 | 58 | 0.100 |
Why?
|
| Cyclohexanones | 1 | 2012 | 30 | 0.100 |
Why?
|
| Immunoglobulin G | 3 | 2013 | 4568 | 0.100 |
Why?
|
| Immunosuppressive Agents | 3 | 2005 | 4206 | 0.100 |
Why?
|
| RNA, Messenger | 12 | 2015 | 12800 | 0.100 |
Why?
|
| Piperazines | 5 | 2009 | 2554 | 0.100 |
Why?
|
| Cryoglobulinemia | 1 | 2012 | 84 | 0.100 |
Why?
|
| Epoxy Compounds | 1 | 2012 | 137 | 0.100 |
Why?
|
| Transcription Factors | 10 | 2023 | 12168 | 0.100 |
Why?
|
| Breast Neoplasms | 3 | 2022 | 21206 | 0.100 |
Why?
|
| Quinoxalines | 1 | 2014 | 297 | 0.100 |
Why?
|
| Thiocyanates | 1 | 2011 | 70 | 0.090 |
Why?
|
| Isothiocyanates | 1 | 2011 | 48 | 0.090 |
Why?
|
| Dendritic Cells | 4 | 2009 | 2747 | 0.090 |
Why?
|
| Antibodies, Neutralizing | 2 | 2013 | 2011 | 0.090 |
Why?
|
| Proto-Oncogene Proteins c-abl | 2 | 2014 | 145 | 0.090 |
Why?
|
| Depsipeptides | 2 | 2008 | 96 | 0.090 |
Why?
|
| Hydroquinones | 2 | 2009 | 34 | 0.090 |
Why?
|
| MAP Kinase Kinase 2 | 2 | 2010 | 93 | 0.090 |
Why?
|
| Phosphoproteins | 2 | 2014 | 2451 | 0.090 |
Why?
|
| Sp1 Transcription Factor | 1 | 2011 | 143 | 0.090 |
Why?
|
| DNA, Neoplasm | 5 | 2007 | 1744 | 0.090 |
Why?
|
| HIV Envelope Protein gp120 | 2 | 1992 | 925 | 0.090 |
Why?
|
| Immunotherapy | 4 | 2009 | 4755 | 0.090 |
Why?
|
| Neoplasms | 8 | 2018 | 22371 | 0.090 |
Why?
|
| Biphenyl Compounds | 2 | 2006 | 1026 | 0.090 |
Why?
|
| Oligopeptides | 2 | 2014 | 1194 | 0.090 |
Why?
|
| Heterocyclic Compounds | 2 | 2009 | 245 | 0.090 |
Why?
|
| Growth Inhibitors | 2 | 2002 | 375 | 0.090 |
Why?
|
| B-Cell Activating Factor | 2 | 2007 | 116 | 0.090 |
Why?
|
| Cytochrome c Group | 4 | 2003 | 123 | 0.090 |
Why?
|
| Transfection | 10 | 2009 | 5755 | 0.090 |
Why?
|
| Cell Cycle Proteins | 5 | 2023 | 3445 | 0.090 |
Why?
|
| T-Lymphocytes | 6 | 2013 | 10266 | 0.090 |
Why?
|
| Pyrazoles | 4 | 2020 | 2028 | 0.080 |
Why?
|
| Recombinant Proteins | 10 | 2007 | 6514 | 0.080 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 3 | 2009 | 627 | 0.080 |
Why?
|
| Genomic Instability | 1 | 2014 | 716 | 0.080 |
Why?
|
| Epigenesis, Genetic | 5 | 2024 | 3833 | 0.080 |
Why?
|
| TCF Transcription Factors | 2 | 2007 | 138 | 0.080 |
Why?
|
| Adamantane | 2 | 2009 | 148 | 0.080 |
Why?
|
| Cell Differentiation | 11 | 2016 | 11669 | 0.080 |
Why?
|
| Cyclin-Dependent Kinases | 2 | 2021 | 663 | 0.080 |
Why?
|
| Receptor-Interacting Protein Serine-Threonine Kinase 2 | 1 | 2009 | 32 | 0.080 |
Why?
|
| Proto-Oncogene Proteins c-bcl-6 | 1 | 2010 | 190 | 0.080 |
Why?
|
| Transcriptional Activation | 3 | 2011 | 1750 | 0.080 |
Why?
|
| Immunoconjugates | 2 | 2009 | 975 | 0.080 |
Why?
|
| Ubiquitin Thiolesterase | 1 | 2012 | 465 | 0.080 |
Why?
|
| Nitrofurans | 1 | 2008 | 6 | 0.080 |
Why?
|
| Proto-Oncogene Proteins c-maf | 1 | 2009 | 69 | 0.080 |
Why?
|
| Drug Design | 3 | 2013 | 1046 | 0.080 |
Why?
|
| Protein Tyrosine Phosphatases | 2 | 2001 | 458 | 0.080 |
Why?
|
| Urea | 1 | 2011 | 448 | 0.080 |
Why?
|
| Bone Remodeling | 2 | 2009 | 583 | 0.080 |
Why?
|
| Immunization, Passive | 3 | 2005 | 619 | 0.080 |
Why?
|
| Cerulenin | 1 | 2008 | 7 | 0.080 |
Why?
|
| Protein Kinases | 2 | 2006 | 1611 | 0.080 |
Why?
|
| Receptors, Interleukin-6 | 4 | 2005 | 224 | 0.080 |
Why?
|
| Activins | 1 | 2010 | 211 | 0.080 |
Why?
|
| Endothelial Cells | 4 | 2019 | 3589 | 0.080 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 3 | 2007 | 2271 | 0.080 |
Why?
|
| Clinical Trials, Phase II as Topic | 5 | 2012 | 640 | 0.080 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 2 | 2009 | 5717 | 0.080 |
Why?
|
| Lymphocytes | 6 | 2005 | 2614 | 0.070 |
Why?
|
| Thiophenes | 1 | 2012 | 570 | 0.070 |
Why?
|
| Autophagy | 4 | 2024 | 1349 | 0.070 |
Why?
|
| Fluorescent Antibody Technique | 4 | 2014 | 2474 | 0.070 |
Why?
|
| Osteolysis | 1 | 2010 | 274 | 0.070 |
Why?
|
| Azepines | 1 | 2010 | 329 | 0.070 |
Why?
|
| Inhibitory Concentration 50 | 2 | 2007 | 464 | 0.070 |
Why?
|
| Salvage Therapy | 2 | 2006 | 1273 | 0.070 |
Why?
|
| Receptors, CCR1 | 1 | 2007 | 30 | 0.070 |
Why?
|
| Niacinamide | 1 | 2010 | 418 | 0.070 |
Why?
|
| Receptor, IGF Type 1 | 3 | 2005 | 384 | 0.070 |
Why?
|
| Jaw Diseases | 1 | 2008 | 91 | 0.070 |
Why?
|
| Paracrine Communication | 3 | 2006 | 278 | 0.070 |
Why?
|
| Endoplasmic Reticulum | 3 | 2008 | 1133 | 0.070 |
Why?
|
| Trans-Activators | 5 | 2005 | 2857 | 0.070 |
Why?
|
| Cell Nucleus | 4 | 2004 | 2885 | 0.070 |
Why?
|
| Survival Rate | 8 | 2013 | 12840 | 0.070 |
Why?
|
| Monocytes | 1 | 2016 | 2605 | 0.070 |
Why?
|
| Anthracenes | 2 | 2003 | 83 | 0.070 |
Why?
|
| Methylation | 2 | 2021 | 1078 | 0.070 |
Why?
|
| Cyclins | 3 | 2005 | 606 | 0.070 |
Why?
|
| Azo Compounds | 1 | 2007 | 116 | 0.070 |
Why?
|
| Phorbol Esters | 1 | 2006 | 109 | 0.070 |
Why?
|
| Sulfonamides | 2 | 2006 | 1982 | 0.070 |
Why?
|
| Benzamides | 3 | 2023 | 1379 | 0.070 |
Why?
|
| Inhibitor of Apoptosis Proteins | 1 | 2007 | 200 | 0.070 |
Why?
|
| RNA Interference | 3 | 2014 | 2832 | 0.070 |
Why?
|
| Cytotoxins | 1 | 2007 | 154 | 0.070 |
Why?
|
| Leukemia, B-Cell | 1 | 2006 | 86 | 0.070 |
Why?
|
| Mitochondria | 6 | 2005 | 3681 | 0.070 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 6 | 2010 | 3814 | 0.070 |
Why?
|
| 6-Ketoprostaglandin F1 alpha | 1 | 2006 | 80 | 0.070 |
Why?
|
| Treatment Outcome | 18 | 2018 | 65371 | 0.070 |
Why?
|
| Isoenzymes | 3 | 2007 | 1688 | 0.070 |
Why?
|
| Nitrophenols | 1 | 2006 | 169 | 0.070 |
Why?
|
| Osteonecrosis | 1 | 2008 | 230 | 0.070 |
Why?
|
| Proto-Oncogene Proteins c-jun | 1 | 2007 | 287 | 0.070 |
Why?
|
| Antibodies | 2 | 2007 | 2421 | 0.060 |
Why?
|
| Receptors, Transforming Growth Factor beta | 2 | 2004 | 304 | 0.060 |
Why?
|
| Naphthalenes | 1 | 2006 | 198 | 0.060 |
Why?
|
| Flavoproteins | 1 | 2005 | 40 | 0.060 |
Why?
|
| Transcription, Genetic | 4 | 2016 | 7608 | 0.060 |
Why?
|
| Nanoparticles | 4 | 2024 | 1985 | 0.060 |
Why?
|
| Transplantation, Autologous | 3 | 2005 | 2120 | 0.060 |
Why?
|
| IMP Dehydrogenase | 1 | 2005 | 34 | 0.060 |
Why?
|
| Superoxides | 2 | 2004 | 389 | 0.060 |
Why?
|
| Rifabutin | 1 | 2005 | 59 | 0.060 |
Why?
|
| Bone Marrow Neoplasms | 1 | 2006 | 101 | 0.060 |
Why?
|
| Hydrolases | 1 | 2006 | 146 | 0.060 |
Why?
|
| Azacitidine | 1 | 2007 | 336 | 0.060 |
Why?
|
| Protein Subunits | 1 | 2009 | 943 | 0.060 |
Why?
|
| Combined Modality Therapy | 6 | 2010 | 8542 | 0.060 |
Why?
|
| Neoplasms, Glandular and Epithelial | 1 | 2009 | 489 | 0.060 |
Why?
|
| Tumor Burden | 4 | 2014 | 1906 | 0.060 |
Why?
|
| Propylene Glycols | 1 | 2005 | 91 | 0.060 |
Why?
|
| cdc25 Phosphatases | 1 | 2005 | 60 | 0.060 |
Why?
|
| Wnt Proteins | 1 | 2009 | 725 | 0.060 |
Why?
|
| DNA-Activated Protein Kinase | 2 | 2002 | 111 | 0.060 |
Why?
|
| Antibiotics, Antineoplastic | 2 | 2014 | 681 | 0.060 |
Why?
|
| HIV Antibodies | 1 | 1992 | 1341 | 0.060 |
Why?
|
| G2 Phase | 1 | 2005 | 134 | 0.060 |
Why?
|
| bcl-X Protein | 1 | 2006 | 412 | 0.060 |
Why?
|
| Membrane Proteins | 4 | 2021 | 7876 | 0.060 |
Why?
|
| Bone Regeneration | 1 | 2008 | 443 | 0.060 |
Why?
|
| Receptors, Immunologic | 2 | 2009 | 1418 | 0.060 |
Why?
|
| Carrier Proteins | 3 | 2003 | 4937 | 0.060 |
Why?
|
| Drug Resistance | 4 | 2003 | 1599 | 0.060 |
Why?
|
| Peptides | 4 | 2018 | 4354 | 0.060 |
Why?
|
| Lignans | 1 | 2005 | 83 | 0.060 |
Why?
|
| Neutralization Tests | 2 | 2000 | 739 | 0.060 |
Why?
|
| Organic Chemicals | 1 | 2005 | 211 | 0.060 |
Why?
|
| Mice, Inbred NOD | 4 | 2014 | 1837 | 0.060 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 6 | 2 | 2001 | 121 | 0.060 |
Why?
|
| Syndecans | 4 | 2005 | 75 | 0.060 |
Why?
|
| Glucocorticoids | 4 | 2009 | 2167 | 0.060 |
Why?
|
| Antigens, Surface | 1 | 2009 | 1617 | 0.060 |
Why?
|
| DNA Topoisomerases, Type I | 1 | 2004 | 108 | 0.060 |
Why?
|
| Caveolins | 1 | 2004 | 102 | 0.060 |
Why?
|
| Chemokine CXCL12 | 2 | 2007 | 457 | 0.060 |
Why?
|
| Endodeoxyribonucleases | 1 | 2005 | 165 | 0.060 |
Why?
|
| Time Factors | 9 | 2010 | 40218 | 0.060 |
Why?
|
| DNA Repair | 3 | 2015 | 2050 | 0.060 |
Why?
|
| Cytokine Receptor gp130 | 2 | 2003 | 66 | 0.060 |
Why?
|
| CDC2 Protein Kinase | 1 | 2005 | 212 | 0.060 |
Why?
|
| DNA Replication | 3 | 2015 | 1427 | 0.060 |
Why?
|
| Contactins | 1 | 2003 | 21 | 0.060 |
Why?
|
| Bone Density Conservation Agents | 2 | 2009 | 797 | 0.060 |
Why?
|
| Caspase 7 | 1 | 2003 | 51 | 0.060 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2005 | 611 | 0.060 |
Why?
|
| Membrane Potentials | 5 | 2005 | 1090 | 0.060 |
Why?
|
| Immunomagnetic Separation | 2 | 2003 | 78 | 0.060 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2022 | 9419 | 0.060 |
Why?
|
| Oleanolic Acid | 1 | 2003 | 43 | 0.060 |
Why?
|
| Models, Animal | 2 | 2007 | 2120 | 0.060 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 11 | 2 | 2001 | 224 | 0.050 |
Why?
|
| Biological Therapy | 1 | 2005 | 140 | 0.050 |
Why?
|
| Drug Discovery | 1 | 2011 | 1068 | 0.050 |
Why?
|
| RANK Ligand | 3 | 2012 | 321 | 0.050 |
Why?
|
| Genes, Immunoglobulin | 1 | 2004 | 286 | 0.050 |
Why?
|
| Calreticulin | 1 | 2024 | 115 | 0.050 |
Why?
|
| RNA | 2 | 2023 | 2720 | 0.050 |
Why?
|
| Ubiquitin-Protein Ligase Complexes | 1 | 2004 | 170 | 0.050 |
Why?
|
| Reactive Oxygen Species | 3 | 2017 | 2149 | 0.050 |
Why?
|
| Phthalazines | 2 | 2003 | 397 | 0.050 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2007 | 801 | 0.050 |
Why?
|
| Tyrosine | 3 | 2004 | 1427 | 0.050 |
Why?
|
| Telomere | 3 | 2003 | 944 | 0.050 |
Why?
|
| Drug Therapy, Combination | 5 | 2016 | 6316 | 0.050 |
Why?
|
| Caveolae | 1 | 2002 | 54 | 0.050 |
Why?
|
| DNA | 4 | 2005 | 7214 | 0.050 |
Why?
|
| B-Cell Maturation Antigen | 1 | 2023 | 149 | 0.050 |
Why?
|
| Ferric Compounds | 1 | 2024 | 376 | 0.050 |
Why?
|
| Naphthoquinones | 1 | 2002 | 60 | 0.050 |
Why?
|
| Phosphoserine | 1 | 2002 | 204 | 0.050 |
Why?
|
| Lymphopoiesis | 1 | 2023 | 133 | 0.050 |
Why?
|
| 3',5'-Cyclic-AMP Phosphodiesterases | 1 | 2001 | 50 | 0.050 |
Why?
|
| bcl-Associated Death Protein | 1 | 2002 | 102 | 0.050 |
Why?
|
| Bone and Bones | 2 | 2009 | 2589 | 0.050 |
Why?
|
| Integrin alpha4beta1 | 2 | 2014 | 119 | 0.050 |
Why?
|
| Cyclic Nucleotide Phosphodiesterases, Type 4 | 1 | 2001 | 42 | 0.050 |
Why?
|
| Immunohistochemistry | 6 | 2014 | 11095 | 0.050 |
Why?
|
| Solubility | 2 | 2014 | 1083 | 0.050 |
Why?
|
| Chromones | 1 | 2001 | 148 | 0.050 |
Why?
|
| TNF Receptor-Associated Factor 2 | 1 | 2021 | 56 | 0.050 |
Why?
|
| Integrin alpha4 | 1 | 2001 | 88 | 0.050 |
Why?
|
| Retinoblastoma-Binding Protein 2 | 1 | 2021 | 35 | 0.050 |
Why?
|
| Porphyrins | 1 | 2003 | 352 | 0.050 |
Why?
|
| Male | 27 | 2016 | 364719 | 0.050 |
Why?
|
| Cyclin-Dependent Kinase 9 | 1 | 2021 | 68 | 0.050 |
Why?
|
| Homeostasis | 1 | 2012 | 3348 | 0.050 |
Why?
|
| Camptothecin | 1 | 2004 | 600 | 0.050 |
Why?
|
| Interleukin-2 | 2 | 2005 | 1895 | 0.050 |
Why?
|
| Genes, cdc | 1 | 2021 | 113 | 0.050 |
Why?
|
| Hybridomas | 2 | 2000 | 444 | 0.040 |
Why?
|
| Phosphodiesterase Inhibitors | 1 | 2001 | 213 | 0.040 |
Why?
|
| Necrosis | 1 | 2005 | 1616 | 0.040 |
Why?
|
| Pyridazines | 1 | 2002 | 203 | 0.040 |
Why?
|
| Neoplasms, Experimental | 2 | 2003 | 1230 | 0.040 |
Why?
|
| Paraproteinemias | 1 | 2003 | 252 | 0.040 |
Why?
|
| Cytotoxicity Tests, Immunologic | 3 | 2006 | 317 | 0.040 |
Why?
|
| Nitriles | 2 | 2020 | 980 | 0.040 |
Why?
|
| Oligonucleotides | 1 | 2003 | 563 | 0.040 |
Why?
|
| STAT2 Transcription Factor | 1 | 2000 | 27 | 0.040 |
Why?
|
| Cell Lineage | 1 | 2009 | 2575 | 0.040 |
Why?
|
| Leukemia | 1 | 2008 | 1519 | 0.040 |
Why?
|
| Flavonoids | 2 | 2001 | 447 | 0.040 |
Why?
|
| Antigens, Nuclear | 1 | 2000 | 183 | 0.040 |
Why?
|
| Female | 27 | 2022 | 397192 | 0.040 |
Why?
|
| Lymphocyte Function-Associated Antigen-1 | 1 | 2001 | 381 | 0.040 |
Why?
|
| Janus Kinase 1 | 1 | 2000 | 108 | 0.040 |
Why?
|
| Models, Chemical | 1 | 2002 | 611 | 0.040 |
Why?
|
| Ribosomes | 1 | 2023 | 497 | 0.040 |
Why?
|
| Mice, Nude | 4 | 2009 | 3623 | 0.040 |
Why?
|
| Interferon-gamma | 4 | 2015 | 3160 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 13 | 2 | 2013 | 192 | 0.040 |
Why?
|
| Glutathione Transferase | 1 | 2001 | 564 | 0.040 |
Why?
|
| Clinical Trials, Phase III as Topic | 2 | 2018 | 879 | 0.040 |
Why?
|
| Bone Diseases | 1 | 2002 | 416 | 0.040 |
Why?
|
| CD40 Ligand | 3 | 2005 | 528 | 0.040 |
Why?
|
| Nucleotidyltransferases | 1 | 2021 | 242 | 0.040 |
Why?
|
| Case-Control Studies | 6 | 2021 | 22291 | 0.040 |
Why?
|
| Chromatin | 2 | 2023 | 2981 | 0.040 |
Why?
|
| Cyclin-Dependent Kinase 6 | 1 | 2022 | 354 | 0.040 |
Why?
|
| Vascular Cell Adhesion Molecule-1 | 1 | 2001 | 693 | 0.040 |
Why?
|
| Adenosine Triphosphate | 1 | 2005 | 2004 | 0.040 |
Why?
|
| Polysaccharides | 1 | 2005 | 1024 | 0.040 |
Why?
|
| Colony-Forming Units Assay | 2 | 2009 | 351 | 0.040 |
Why?
|
| STAT1 Transcription Factor | 1 | 2000 | 343 | 0.040 |
Why?
|
| Immunoprecipitation | 2 | 2014 | 874 | 0.040 |
Why?
|
| Translocation, Genetic | 1 | 2004 | 1394 | 0.040 |
Why?
|
| Crystallography, X-Ray | 2 | 2013 | 1951 | 0.040 |
Why?
|
| Cyclopentanes | 1 | 2018 | 87 | 0.040 |
Why?
|
| Carcinoma | 1 | 2009 | 2332 | 0.040 |
Why?
|
| RNA Splicing | 1 | 2023 | 905 | 0.040 |
Why?
|
| Cyclin-Dependent Kinase 4 | 1 | 2022 | 565 | 0.040 |
Why?
|
| Neoplastic Stem Cells | 2 | 2017 | 1351 | 0.040 |
Why?
|
| Antineoplastic Agents, Hormonal | 2 | 2006 | 1536 | 0.040 |
Why?
|
| Steroids | 1 | 2003 | 938 | 0.040 |
Why?
|
| Chemokine CCL3 | 2 | 2007 | 85 | 0.040 |
Why?
|
| Cell Fusion | 3 | 2007 | 294 | 0.040 |
Why?
|
| Lymphoma | 2 | 2004 | 1898 | 0.040 |
Why?
|
| TNF-Related Apoptosis-Inducing Ligand | 3 | 2005 | 195 | 0.040 |
Why?
|
| Acid Phosphatase | 2 | 2007 | 141 | 0.040 |
Why?
|
| Alternative Splicing | 1 | 2023 | 1105 | 0.040 |
Why?
|
| X-Linked Inhibitor of Apoptosis Protein | 2 | 2012 | 61 | 0.040 |
Why?
|
| Calcium-Calmodulin-Dependent Protein Kinases | 1 | 1999 | 492 | 0.040 |
Why?
|
| HIV-1 | 2 | 1992 | 6961 | 0.040 |
Why?
|
| Multiprotein Complexes | 2 | 2015 | 1110 | 0.040 |
Why?
|
| Ribonucleoside Diphosphate Reductase | 1 | 2017 | 31 | 0.040 |
Why?
|
| Immunoenzyme Techniques | 2 | 2012 | 1703 | 0.040 |
Why?
|
| Gene Expression Regulation | 3 | 2005 | 11928 | 0.040 |
Why?
|
| Clinical Trials, Phase I as Topic | 2 | 2010 | 330 | 0.030 |
Why?
|
| Osteogenesis | 3 | 2009 | 1288 | 0.030 |
Why?
|
| Anticarcinogenic Agents | 2 | 2010 | 251 | 0.030 |
Why?
|
| Mutation | 3 | 2016 | 30238 | 0.030 |
Why?
|
| Culture Media, Serum-Free | 2 | 2009 | 148 | 0.030 |
Why?
|
| Disease Progression | 6 | 2015 | 13671 | 0.030 |
Why?
|
| Benzylamines | 2 | 2009 | 251 | 0.030 |
Why?
|
| Disease Models, Animal | 4 | 2014 | 18349 | 0.030 |
Why?
|
| Macrophage Colony-Stimulating Factor | 2 | 2007 | 186 | 0.030 |
Why?
|
| RNA Polymerase II | 1 | 2021 | 549 | 0.030 |
Why?
|
| Janus Kinase 2 | 1 | 2000 | 561 | 0.030 |
Why?
|
| Remission Induction | 3 | 2010 | 2410 | 0.030 |
Why?
|
| Precancerous Conditions | 1 | 2003 | 985 | 0.030 |
Why?
|
| Glutamate-Cysteine Ligase | 1 | 2016 | 24 | 0.030 |
Why?
|
| Cancer Vaccines | 1 | 2004 | 1041 | 0.030 |
Why?
|
| Autoantigens | 1 | 2000 | 890 | 0.030 |
Why?
|
| Gene Expression | 3 | 2007 | 7598 | 0.030 |
Why?
|
| Immunophenotyping | 3 | 2009 | 1864 | 0.030 |
Why?
|
| ets-Domain Protein Elk-1 | 1 | 2015 | 38 | 0.030 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2006 | 1437 | 0.030 |
Why?
|
| Cyclin D2 | 1 | 2016 | 98 | 0.030 |
Why?
|
| Lentivirus | 2 | 2009 | 518 | 0.030 |
Why?
|
| Antigens, Neoplasm | 2 | 2018 | 1997 | 0.030 |
Why?
|
| Retinoblastoma Protein | 1 | 1999 | 671 | 0.030 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2006 | 1642 | 0.030 |
Why?
|
| Multidrug Resistance-Associated Proteins | 1 | 2015 | 105 | 0.030 |
Why?
|
| DNA Helicases | 1 | 2000 | 854 | 0.030 |
Why?
|
| Complement System Proteins | 2 | 2003 | 738 | 0.030 |
Why?
|
| Genes, Tumor Suppressor | 2 | 2014 | 1062 | 0.030 |
Why?
|
| Chemotaxis | 2 | 2009 | 600 | 0.030 |
Why?
|
| Electrophoretic Mobility Shift Assay | 2 | 2006 | 294 | 0.030 |
Why?
|
| Immunity | 1 | 2021 | 1003 | 0.030 |
Why?
|
| Mutagens | 1 | 2015 | 181 | 0.030 |
Why?
|
| Gene Expression Regulation, Enzymologic | 2 | 2010 | 1169 | 0.030 |
Why?
|
| Chromosome Deletion | 2 | 2013 | 1385 | 0.030 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2002 | 1627 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 4 | 2017 | 10399 | 0.030 |
Why?
|
| DNA Primers | 2 | 2014 | 2828 | 0.030 |
Why?
|
| Genes, bcl-2 | 2 | 2005 | 119 | 0.030 |
Why?
|
| Exosomes | 1 | 2019 | 422 | 0.030 |
Why?
|
| Chromosomal Instability | 1 | 2015 | 176 | 0.030 |
Why?
|
| Chromosome Aberrations | 2 | 2011 | 1778 | 0.030 |
Why?
|
| Neovascularization, Physiologic | 3 | 2006 | 1369 | 0.030 |
Why?
|
| Oximes | 1 | 2015 | 303 | 0.030 |
Why?
|
| Maximum Tolerated Dose | 2 | 2009 | 899 | 0.030 |
Why?
|
| Ubiquitination | 1 | 2018 | 1009 | 0.030 |
Why?
|
| Bone Resorption | 2 | 2007 | 728 | 0.030 |
Why?
|
| Phase Transition | 1 | 2013 | 70 | 0.030 |
Why?
|
| HSP27 Heat-Shock Proteins | 2 | 2003 | 67 | 0.030 |
Why?
|
| Stem Cell Niche | 1 | 2016 | 347 | 0.030 |
Why?
|
| Molecular Structure | 2 | 2008 | 1883 | 0.030 |
Why?
|
| Epitopes | 3 | 2000 | 2528 | 0.030 |
Why?
|
| Middle Aged | 16 | 2014 | 223492 | 0.030 |
Why?
|
| Ligands | 3 | 2007 | 3284 | 0.030 |
Why?
|
| Solutions | 1 | 2013 | 409 | 0.030 |
Why?
|
| Disease-Free Survival | 3 | 2011 | 6847 | 0.030 |
Why?
|
| Administration, Oral | 3 | 2006 | 4030 | 0.030 |
Why?
|
| Anti-HIV Agents | 1 | 2009 | 4573 | 0.030 |
Why?
|
| Amino Acid Chloromethyl Ketones | 1 | 2012 | 68 | 0.030 |
Why?
|
| Fibronectins | 2 | 2009 | 722 | 0.030 |
Why?
|
| Buffers | 1 | 2012 | 143 | 0.030 |
Why?
|
| Sulfones | 1 | 2015 | 448 | 0.030 |
Why?
|
| Antioxidants | 2 | 2015 | 1673 | 0.030 |
Why?
|
| Amyloidosis | 1 | 2000 | 878 | 0.030 |
Why?
|
| Cell Culture Techniques | 1 | 2000 | 1667 | 0.030 |
Why?
|
| Colorectal Neoplasms | 1 | 2012 | 6974 | 0.020 |
Why?
|
| Oxazines | 1 | 2014 | 358 | 0.020 |
Why?
|
| Autoantibodies | 1 | 2000 | 2121 | 0.020 |
Why?
|
| 3' Untranslated Regions | 1 | 2014 | 515 | 0.020 |
Why?
|
| Sulfoxides | 1 | 2011 | 47 | 0.020 |
Why?
|
| Antigen-Presenting Cells | 1 | 2015 | 960 | 0.020 |
Why?
|
| Temperature | 2 | 2013 | 2234 | 0.020 |
Why?
|
| Phosphatidylinositol 3-Kinase | 1 | 2012 | 125 | 0.020 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2012 | 379 | 0.020 |
Why?
|
| Crystallization | 1 | 2012 | 520 | 0.020 |
Why?
|
| Genomics | 1 | 2007 | 5926 | 0.020 |
Why?
|
| HLA-DR Antigens | 1 | 2013 | 609 | 0.020 |
Why?
|
| Oxidation-Reduction | 1 | 2017 | 2227 | 0.020 |
Why?
|
| Aged | 12 | 2014 | 171504 | 0.020 |
Why?
|
| Immunologic Memory | 1 | 2018 | 1377 | 0.020 |
Why?
|
| Membrane Potential, Mitochondrial | 1 | 2012 | 297 | 0.020 |
Why?
|
| Liposomes | 1 | 2014 | 790 | 0.020 |
Why?
|
| Luminescent Proteins | 2 | 2003 | 838 | 0.020 |
Why?
|
| Receptors, Glucocorticoid | 2 | 2003 | 309 | 0.020 |
Why?
|
| Endothelium, Vascular | 3 | 2010 | 4427 | 0.020 |
Why?
|
| X-Ray Microtomography | 1 | 2013 | 457 | 0.020 |
Why?
|
| Adenine | 1 | 2016 | 995 | 0.020 |
Why?
|
| Particle Size | 1 | 2014 | 1649 | 0.020 |
Why?
|
| Epigenomics | 1 | 2016 | 960 | 0.020 |
Why?
|
| Focal Adhesion Kinase 2 | 2 | 2000 | 87 | 0.020 |
Why?
|
| Subtraction Technique | 2 | 2003 | 517 | 0.020 |
Why?
|
| Survival Analysis | 3 | 2010 | 10101 | 0.020 |
Why?
|
| Integrins | 1 | 2014 | 842 | 0.020 |
Why?
|
| Safety | 2 | 2006 | 1159 | 0.020 |
Why?
|
| Smad2 Protein | 1 | 2010 | 144 | 0.020 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-1 | 2 | 2003 | 560 | 0.020 |
Why?
|
| Umbilical Veins | 1 | 2010 | 424 | 0.020 |
Why?
|
| Suppressor of Cytokine Signaling Proteins | 1 | 2010 | 178 | 0.020 |
Why?
|
| Adult | 12 | 2014 | 223646 | 0.020 |
Why?
|
| Sensation Disorders | 1 | 2010 | 160 | 0.020 |
Why?
|
| Cytosol | 2 | 2003 | 887 | 0.020 |
Why?
|
| Peripheral Nervous System Diseases | 2 | 2006 | 716 | 0.020 |
Why?
|
| Urochordata | 1 | 2008 | 19 | 0.020 |
Why?
|
| Molecular Chaperones | 2 | 2003 | 762 | 0.020 |
Why?
|
| Butadienes | 1 | 2008 | 107 | 0.020 |
Why?
|
| RNA, Neoplasm | 2 | 2002 | 749 | 0.020 |
Why?
|
| Cytoprotection | 1 | 2009 | 200 | 0.020 |
Why?
|
| Cluster Analysis | 1 | 2015 | 2732 | 0.020 |
Why?
|
| Melanoma, Experimental | 1 | 2011 | 559 | 0.020 |
Why?
|
| Oligodeoxyribonucleotides | 1 | 2009 | 705 | 0.020 |
Why?
|
| Random Allocation | 1 | 2012 | 2396 | 0.020 |
Why?
|
| Depression, Chemical | 1 | 2007 | 186 | 0.020 |
Why?
|
| Base Sequence | 2 | 2014 | 12421 | 0.020 |
Why?
|
| Chemokine CCL4 | 1 | 2007 | 127 | 0.020 |
Why?
|
| Seawater | 1 | 2008 | 126 | 0.020 |
Why?
|
| Green Fluorescent Proteins | 2 | 2003 | 2065 | 0.020 |
Why?
|
| Macrophage Inflammatory Proteins | 1 | 2007 | 122 | 0.020 |
Why?
|
| Tissue Distribution | 1 | 2012 | 2300 | 0.020 |
Why?
|
| Extracellular Matrix Proteins | 2 | 2002 | 832 | 0.020 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2012 | 2486 | 0.020 |
Why?
|
| Organ Specificity | 1 | 2012 | 1968 | 0.020 |
Why?
|
| Deoxycytidine | 1 | 2012 | 887 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2005 | 15948 | 0.020 |
Why?
|
| Genes, Reporter | 2 | 2002 | 1524 | 0.020 |
Why?
|
| Genes, fos | 1 | 2007 | 176 | 0.020 |
Why?
|
| Albumins | 1 | 2010 | 577 | 0.020 |
Why?
|
| Immunity, Cellular | 2 | 2004 | 1561 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2005 | 20227 | 0.020 |
Why?
|
| Integrin alphaVbeta3 | 1 | 2007 | 103 | 0.020 |
Why?
|
| Microscopy, Fluorescence | 2 | 2004 | 2633 | 0.020 |
Why?
|
| Thrombocytosis | 1 | 2007 | 88 | 0.020 |
Why?
|
| Fluorouracil | 1 | 2012 | 1652 | 0.020 |
Why?
|
| Drug Evaluation | 1 | 2008 | 642 | 0.020 |
Why?
|
| Leukemia, Erythroblastic, Acute | 1 | 2007 | 176 | 0.020 |
Why?
|
| Receptors, Interleukin-4 | 1 | 2006 | 66 | 0.020 |
Why?
|
| Ribonucleotide Reductases | 1 | 2006 | 75 | 0.020 |
Why?
|
| Hematopoietic Stem Cells | 2 | 2009 | 3409 | 0.020 |
Why?
|
| Peptides, Cyclic | 1 | 2008 | 391 | 0.020 |
Why?
|
| Hematologic Diseases | 1 | 2010 | 498 | 0.020 |
Why?
|
| Leukocytosis | 1 | 2007 | 251 | 0.020 |
Why?
|
| Toll-Like Receptors | 1 | 2009 | 582 | 0.020 |
Why?
|
| Transcription Factor 7-Like 2 Protein | 1 | 2006 | 152 | 0.020 |
Why?
|
| Chorioallantoic Membrane | 1 | 2006 | 50 | 0.020 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2015 | 2059 | 0.020 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 1 | 2010 | 905 | 0.020 |
Why?
|
| Tubulin Modulators | 1 | 2006 | 106 | 0.020 |
Why?
|
| Neoplasm Invasiveness | 1 | 2014 | 3620 | 0.020 |
Why?
|
| Apoptosis Inducing Factor | 1 | 2005 | 51 | 0.020 |
Why?
|
| Molecular Mimicry | 1 | 2006 | 213 | 0.020 |
Why?
|
| Somatomedins | 1 | 2006 | 179 | 0.020 |
Why?
|
| Stem Cells | 2 | 2010 | 3537 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2014 | 6229 | 0.020 |
Why?
|
| Angiopoietin-1 | 1 | 2006 | 133 | 0.020 |
Why?
|
| raf Kinases | 1 | 2005 | 117 | 0.020 |
Why?
|
| Antigen-Antibody Reactions | 1 | 2005 | 342 | 0.020 |
Why?
|
| Computational Biology | 1 | 2017 | 3568 | 0.020 |
Why?
|
| Lipopolysaccharides | 1 | 2013 | 2219 | 0.020 |
Why?
|
| Stimulation, Chemical | 1 | 2005 | 305 | 0.020 |
Why?
|
| Dose-Response Relationship, Immunologic | 1 | 2005 | 361 | 0.020 |
Why?
|
| Crk-Associated Substrate Protein | 1 | 2004 | 39 | 0.020 |
Why?
|
| Retinoblastoma-Like Protein p130 | 1 | 2004 | 72 | 0.010 |
Why?
|
| Indazoles | 1 | 2006 | 306 | 0.010 |
Why?
|
| Substrate Specificity | 1 | 2009 | 1751 | 0.010 |
Why?
|
| Angiopoietin-2 | 1 | 2006 | 186 | 0.010 |
Why?
|
| HEK293 Cells | 1 | 2014 | 4283 | 0.010 |
Why?
|
| beta 2-Microglobulin | 1 | 2005 | 330 | 0.010 |
Why?
|
| GABA-A Receptor Antagonists | 1 | 2004 | 59 | 0.010 |
Why?
|
| Genetic Vectors | 1 | 2014 | 3402 | 0.010 |
Why?
|
| Smoking | 1 | 2001 | 9092 | 0.010 |
Why?
|
| Aged, 80 and over | 4 | 2014 | 59629 | 0.010 |
Why?
|
| Cell Adhesion Molecules | 1 | 2010 | 1613 | 0.010 |
Why?
|
| Asthenia | 1 | 2004 | 16 | 0.010 |
Why?
|
| bcl-2-Associated X Protein | 1 | 2005 | 281 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-hck | 1 | 2004 | 46 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 2 | 2006 | 6082 | 0.010 |
Why?
|
| Stereoisomerism | 1 | 2005 | 612 | 0.010 |
Why?
|
| Drug Administration Schedule | 1 | 2012 | 4860 | 0.010 |
Why?
|
| Phosphoric Acids | 1 | 2003 | 19 | 0.010 |
Why?
|
| Clone Cells | 1 | 2007 | 1670 | 0.010 |
Why?
|
| Tyrphostins | 1 | 2003 | 63 | 0.010 |
Why?
|
| Hyperplasia | 1 | 2007 | 1151 | 0.010 |
Why?
|
| Oxidative Stress | 1 | 2015 | 3139 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2005 | 24315 | 0.010 |
Why?
|
| Chick Embryo | 1 | 2006 | 975 | 0.010 |
Why?
|
| Microarray Analysis | 1 | 2006 | 753 | 0.010 |
Why?
|
| Lymphocyte Culture Test, Mixed | 1 | 2004 | 510 | 0.010 |
Why?
|
| Antigens, CD19 | 1 | 2007 | 446 | 0.010 |
Why?
|
| Leupeptins | 1 | 2003 | 113 | 0.010 |
Why?
|
| Cytochromes c | 1 | 2004 | 173 | 0.010 |
Why?
|
| Adenocarcinoma | 1 | 2001 | 6395 | 0.010 |
Why?
|
| Galectin 3 | 1 | 2005 | 240 | 0.010 |
Why?
|
| Complement Membrane Attack Complex | 1 | 2003 | 105 | 0.010 |
Why?
|
| Serum Albumin, Bovine | 1 | 2004 | 320 | 0.010 |
Why?
|
| Microfilament Proteins | 1 | 2009 | 1133 | 0.010 |
Why?
|
| Fusion Proteins, bcr-abl | 1 | 2005 | 430 | 0.010 |
Why?
|
| Cell Line, Transformed | 1 | 2005 | 866 | 0.010 |
Why?
|
| Tetrazolium Salts | 1 | 2003 | 92 | 0.010 |
Why?
|
| Models, Molecular | 1 | 2013 | 5403 | 0.010 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 1992 | 2204 | 0.010 |
Why?
|
| Ubiquitin-Conjugating Enzymes | 1 | 2004 | 197 | 0.010 |
Why?
|
| Receptors, Interleukin-2 | 1 | 2005 | 564 | 0.010 |
Why?
|
| Sphingosine | 1 | 2005 | 308 | 0.010 |
Why?
|
| Transcription Factor AP-1 | 1 | 2005 | 321 | 0.010 |
Why?
|
| Receptor Cross-Talk | 1 | 2003 | 118 | 0.010 |
Why?
|
| Phosphotyrosine | 1 | 2004 | 458 | 0.010 |
Why?
|
| Cyclin D1 | 1 | 2005 | 453 | 0.010 |
Why?
|
| Caveolin 1 | 1 | 2004 | 255 | 0.010 |
Why?
|
| Myeloma Proteins | 1 | 2002 | 71 | 0.010 |
Why?
|
| Precipitin Tests | 1 | 2003 | 816 | 0.010 |
Why?
|
| Fatigue | 1 | 2010 | 1557 | 0.010 |
Why?
|
| Deoxyribonuclease I | 1 | 2003 | 228 | 0.010 |
Why?
|
| NFATC Transcription Factors | 1 | 2005 | 393 | 0.010 |
Why?
|
| Isoquinolines | 1 | 2004 | 354 | 0.010 |
Why?
|
| DNA, Viral | 2 | 2000 | 2204 | 0.010 |
Why?
|
| Mesenchymal Stem Cell Transplantation | 1 | 2008 | 507 | 0.010 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2006 | 614 | 0.010 |
Why?
|
| Membrane Microdomains | 1 | 2003 | 205 | 0.010 |
Why?
|
| Injections, Intraperitoneal | 1 | 2003 | 411 | 0.010 |
Why?
|
| Drug Therapy | 1 | 2005 | 504 | 0.010 |
Why?
|
| Mitoxantrone | 1 | 2002 | 148 | 0.010 |
Why?
|
| Enzyme Precursors | 1 | 2002 | 166 | 0.010 |
Why?
|
| Acetylcysteine | 1 | 2003 | 262 | 0.010 |
Why?
|
| Lymphoma, Mantle-Cell | 1 | 2005 | 240 | 0.010 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2004 | 505 | 0.010 |
Why?
|
| Topoisomerase II Inhibitors | 1 | 2002 | 94 | 0.010 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-3 | 1 | 2002 | 118 | 0.010 |
Why?
|
| Topoisomerase I Inhibitors | 1 | 2002 | 70 | 0.010 |
Why?
|
| Cytoskeleton | 1 | 2007 | 1179 | 0.010 |
Why?
|
| src-Family Kinases | 1 | 2004 | 539 | 0.010 |
Why?
|
| Enzyme Induction | 1 | 2002 | 455 | 0.010 |
Why?
|
| Apoptotic Protease-Activating Factor 1 | 1 | 2001 | 21 | 0.010 |
Why?
|
| Urokinase-Type Plasminogen Activator | 1 | 2002 | 324 | 0.010 |
Why?
|
| Twins, Monozygotic | 1 | 2003 | 472 | 0.010 |
Why?
|
| Protein Isoforms | 1 | 2006 | 1715 | 0.010 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2012 | 6526 | 0.010 |
Why?
|
| Receptors, Growth Factor | 1 | 2002 | 324 | 0.010 |
Why?
|
| Diseases in Twins | 1 | 2003 | 447 | 0.010 |
Why?
|
| Leukemia, Plasma Cell | 1 | 2001 | 46 | 0.010 |
Why?
|
| Antigens, CD34 | 1 | 2003 | 657 | 0.010 |
Why?
|
| Stress, Physiological | 1 | 2008 | 1408 | 0.010 |
Why?
|
| Peripheral Blood Stem Cell Transplantation | 1 | 2002 | 263 | 0.010 |
Why?
|
| SH2 Domain-Containing Protein Tyrosine Phosphatases | 1 | 2000 | 43 | 0.010 |
Why?
|
| Fluorescence | 1 | 2003 | 756 | 0.010 |
Why?
|
| G-Quadruplexes | 1 | 2003 | 144 | 0.010 |
Why?
|
| Amides | 1 | 2003 | 451 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-raf | 1 | 2001 | 205 | 0.010 |
Why?
|
| Herpesviridae Infections | 1 | 2002 | 269 | 0.010 |
Why?
|
| Nausea | 1 | 2004 | 682 | 0.010 |
Why?
|
| Oligonucleotides, Antisense | 1 | 2003 | 462 | 0.010 |
Why?
|
| Receptors, Cell Surface | 1 | 2010 | 2819 | 0.010 |
Why?
|
| Antigens, Differentiation | 1 | 2003 | 921 | 0.010 |
Why?
|
| Homeodomain Proteins | 1 | 2010 | 2429 | 0.010 |
Why?
|
| Coloring Agents | 1 | 2003 | 565 | 0.010 |
Why?
|
| Mutation, Missense | 1 | 2009 | 2592 | 0.010 |
Why?
|
| Genes, Dominant | 1 | 2003 | 855 | 0.010 |
Why?
|
| Cell-Free System | 1 | 2000 | 339 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 2 | 2009 | 22379 | 0.010 |
Why?
|
| MAP Kinase Kinase Kinases | 1 | 2001 | 252 | 0.010 |
Why?
|
| Mutagenesis | 1 | 2004 | 1228 | 0.010 |
Why?
|
| Extracellular Matrix | 1 | 2007 | 1738 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 2012 | 17622 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2021 | 39348 | 0.010 |
Why?
|
| Structure-Activity Relationship | 1 | 2005 | 3055 | 0.010 |
Why?
|
| DNA, Complementary | 1 | 2003 | 1989 | 0.010 |
Why?
|
| src Homology Domains | 1 | 2000 | 361 | 0.010 |
Why?
|
| Codon | 1 | 2001 | 599 | 0.010 |
Why?
|
| Fibroblast Growth Factor 2 | 1 | 2001 | 590 | 0.010 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2003 | 892 | 0.010 |
Why?
|
| Interleukin-4 | 1 | 2003 | 1156 | 0.010 |
Why?
|
| Sequence Analysis, Protein | 1 | 2000 | 264 | 0.010 |
Why?
|
| Cell Membrane | 1 | 2009 | 3655 | 0.010 |
Why?
|
| Oncogene Proteins | 1 | 2003 | 717 | 0.010 |
Why?
|
| HeLa Cells | 1 | 2005 | 3074 | 0.010 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2008 | 2055 | 0.010 |
Why?
|
| Jurkat Cells | 1 | 2000 | 740 | 0.010 |
Why?
|
| Serine | 1 | 2003 | 831 | 0.010 |
Why?
|
| Cyclin D | 1 | 1999 | 71 | 0.010 |
Why?
|
| Lymphocyte Count | 1 | 2001 | 794 | 0.010 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 2001 | 587 | 0.010 |
Why?
|
| Radiation, Ionizing | 1 | 1999 | 252 | 0.010 |
Why?
|
| Neoplasm Staging | 1 | 2014 | 11244 | 0.010 |
Why?
|
| Transforming Growth Factor beta | 1 | 2006 | 1996 | 0.010 |
Why?
|
| Protein Folding | 1 | 2002 | 871 | 0.010 |
Why?
|
| Estrogens | 1 | 2005 | 1536 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-kit | 1 | 2002 | 725 | 0.010 |
Why?
|
| Antigen Presentation | 1 | 2004 | 1251 | 0.010 |
Why?
|
| Protein Transport | 1 | 2004 | 1951 | 0.010 |
Why?
|
| Catalytic Domain | 1 | 2000 | 699 | 0.010 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 2000 | 1730 | 0.010 |
Why?
|
| 3T3 Cells | 1 | 2000 | 1084 | 0.010 |
Why?
|
| Antigens, Viral | 1 | 2002 | 995 | 0.010 |
Why?
|
| Androgens | 1 | 2005 | 1281 | 0.010 |
Why?
|
| Oncogenes | 1 | 2003 | 1234 | 0.010 |
Why?
|
| Microcirculation | 1 | 2003 | 1281 | 0.010 |
Why?
|
| Hematopoiesis | 1 | 2007 | 2059 | 0.010 |
Why?
|
| Immunocompromised Host | 1 | 2003 | 863 | 0.010 |
Why?
|
| Genotype | 2 | 2003 | 13045 | 0.010 |
Why?
|
| Constipation | 1 | 2002 | 570 | 0.010 |
Why?
|
| Gamma Rays | 1 | 1999 | 319 | 0.010 |
Why?
|
| Genes, p53 | 1 | 2000 | 714 | 0.010 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2005 | 1375 | 0.010 |
Why?
|
| Neutropenia | 1 | 2002 | 892 | 0.010 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2003 | 2521 | 0.010 |
Why?
|
| Phagocytosis | 1 | 2003 | 1530 | 0.010 |
Why?
|
| Hemoglobins | 1 | 2003 | 1531 | 0.010 |
Why?
|
| Cytoskeletal Proteins | 1 | 2002 | 1327 | 0.010 |
Why?
|
| Drug Interactions | 1 | 2001 | 1419 | 0.010 |
Why?
|
| Diarrhea | 1 | 2004 | 1320 | 0.010 |
Why?
|
| Mice, Transgenic | 1 | 2009 | 9561 | 0.010 |
Why?
|
| Lung Neoplasms | 1 | 2001 | 13586 | 0.010 |
Why?
|
| Venous Thrombosis | 1 | 2006 | 1323 | 0.010 |
Why?
|
| Actins | 1 | 2004 | 2064 | 0.010 |
Why?
|
| Bone Density | 1 | 2009 | 3573 | 0.010 |
Why?
|
| Glycoproteins | 1 | 2003 | 2202 | 0.010 |
Why?
|
| Thiazoles | 1 | 2003 | 1542 | 0.010 |
Why?
|
| Biopsy, Needle | 1 | 2000 | 1622 | 0.010 |
Why?
|
| Neoplasm, Residual | 1 | 2000 | 1015 | 0.010 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2003 | 1767 | 0.010 |
Why?
|
| Forkhead Transcription Factors | 1 | 2002 | 1625 | 0.010 |
Why?
|
| Biopsy | 1 | 2007 | 6793 | 0.010 |
Why?
|
| Pain | 1 | 2010 | 5100 | 0.010 |
Why?
|
| Receptor, erbB-2 | 1 | 2005 | 2603 | 0.010 |
Why?
|
| Thrombocytopenia | 1 | 2002 | 1179 | 0.010 |
Why?
|
| RNA, Viral | 1 | 2002 | 2872 | 0.010 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2003 | 2846 | 0.010 |
Why?
|
| Cholesterol | 1 | 2002 | 2914 | 0.010 |
Why?
|
| Phenotype | 2 | 2003 | 16726 | 0.010 |
Why?
|
| Reference Values | 1 | 2000 | 4938 | 0.010 |
Why?
|
| Hodgkin Disease | 1 | 2000 | 1384 | 0.010 |
Why?
|
| Kinetics | 1 | 2000 | 6329 | 0.010 |
Why?
|
| Nervous System Diseases | 1 | 2002 | 1662 | 0.010 |
Why?
|
| Positron-Emission Tomography | 1 | 2008 | 6669 | 0.010 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2000 | 3740 | 0.010 |
Why?
|
| Protein Binding | 1 | 1999 | 9343 | 0.000 |
Why?
|
| Palliative Care | 1 | 2002 | 3643 | 0.000 |
Why?
|
| Genetic Variation | 1 | 2000 | 6611 | 0.000 |
Why?
|
| Prospective Studies | 1 | 2004 | 54926 | 0.000 |
Why?
|